Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma: Which Stock Should You Track

Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma starts with the core numbers most investors compare within the Pharmaceuticals segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of September 2026 and will shift with daily price moves.

All three names sit in the Pharmaceuticals bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.

Tap to Access Best Research Pieces on Univest

Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma: Company Overview

Aurobindo Pharma is a listed Indian company in the Pharmaceuticals space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.

AstraZeneca Pharma India is a listed Indian company in the Pharmaceuticals space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.

Bal Pharma is a listed Indian company in the Pharmaceuticals space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.

Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma: Valuation and Profitability Snapshot

Metric	Aurobindo Pharma	AstraZeneca Pharma India	Bal Pharma
Market Cap (approx.)	Rs 97,642 crore	Rs 16,780 crore	Rs 174 crore
PE Ratio (TTM)	26.31	98.93	23.97
PB Ratio	2.58	19.23	2.11
Return on Equity (ROE)	9.25%	21.49%	7.64%
EPS (TTM, Rs)	64.49	67.85	4.55
Dividend Yield	0.24%	0.54%	1.10%
Debt to Equity	0.21	0.13	1.94
Book Value per Share (Rs)	658.53	349.12	51.65

Check the Univest Screener for Live Data

On valuation, Aurobindo Pharma trades at a PE of 26.31 and a PB of 2.58, AstraZeneca Pharma India at a PE of 98.93 and a PB of 19.23, while Bal Pharma trades at a PE of 23.97 and a PB of 2.11. On return on equity, the three post 9.25%, 21.49% and 7.64% respectively, and on dividend yield they stand at 0.24%, 0.54% and 1.10%.

Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma: Latest Quarterly Results

Company	Latest Quarter Revenue	Latest Quarter Net Profit	YoY Change (Revenue)	QoQ Change (Revenue)
Aurobindo Pharma	Rs 9,414.58 crore	Rs 1,032.03 crore	+18.1%	+5.0%
AstraZeneca Pharma India	Quarterly revenue and profit figures for AstraZeneca Pharma India were not independently verified this round; readers should check the company's latest exchange filing before relying on a quarter-specific figure.
Bal Pharma	Rs 89.06 crore	Rs 1.14 crore	+33.7%	+6.2%

Quarterly figures above are the most recent reported quarter for each company (Q1 FY28, quarter ended June 2026), compared with the year-ago and preceding quarter where that data was available. A blank cell means the figure could not be independently verified in this pull and should be checked on the company's own exchange filing before use.

Download the Univest iOS App or Univest Android App to track Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma live prices.

What Should Investors Look at Beyond These Numbers?

Beyond the metrics above, investors comparing these three pharmaceuticals names should track quarter-on-quarter revenue and margin trends, management commentary on order books or demand, and any sector-specific regulatory or input-cost developments, since a single-quarter snapshot can shift quickly.

Conclusion

Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma highlights how differently three companies in the same pharmaceuticals segment can score across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.

FAQs on Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma

What is the market cap difference between Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma?

Ans. As of September 2026, Aurobindo Pharma has a market cap of approximately Rs 97,642 crore, AstraZeneca Pharma India is at approximately Rs 16,780 crore, and Bal Pharma is at approximately Rs 174 crore.

Which of the three has the highest PE ratio?

Ans. Among Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma, the PE ratios stand at 26.31, 98.93 and 23.97 respectively as of September 2026.

Which of the three has the highest ROE?

Ans. Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma post ROE of 9.25%, 21.49% and 7.64% respectively as of September 2026.

Which of these three stocks pays the highest dividend yield?

Ans. Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma carry dividend yields of 0.24%, 0.54% and 1.10% respectively.

What is the debt to equity ratio for Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma?

Ans. Aurobindo Pharma carries a debt to equity of 0.21, AstraZeneca Pharma India of 0.13, and Bal Pharma of 1.94.

Which of the three trades at the highest price to book value?

Ans. Aurobindo Pharma, AstraZeneca Pharma India and Bal Pharma trade at price to book ratios of 2.58, 19.23 and 2.11 respectively.

Is one of Aurobindo Pharma, AstraZeneca Pharma India or Bal Pharma better than the others?

Ans. This comparison does not declare one stock better than another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor's own criteria and research.